Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Pediatric Hematology/Oncology Fellowship, Pediatrics, Duke University School of Medicine 2009 - 2013
  • Pediatrics Internship and Residency, Pediatrics, University of Michigan, Ann Arbor 2006 - 2009
  • MD./PhD., University of Michigan, Ann Arbor 2006
• 

  Duke Appointment History

  • Assistant Professor of Pediatrics, Pediatrics, Hematology-Oncology, Pediatrics 2016 - 2020
  • Medical Instructor in the Department of Pediatrics, Pediatrics, Hematology-Oncology, Pediatrics 2013 - 2016
• Expertise
• 

  Subject Headings

  • Neurofibromatosis
  • Neurofibromatosis 1
  • Neurofibromatosis 2
  • Neurofibromatosis in children
  • Oncology
  • Sarcoma
  • Tumors in children
• Research
• 

  Selected Grants

  • A phase 2b trial of the MEK 1/2 inhibitor (MEKi) PD-0325901 in adult and pediatric patient with neurofibromatosis type 1 (NF1)-associated inoperable plexiform neurofibromas (PNs) that are causing significant morbidity awarded by SpringWorks Therapeutics 2020 - 2024
  • Targeting epigenetic dysregulation in pediatric cancer awarded by Dana-Farber Cancer Institute 2019 - 2021
  • MAIN STUDY: Developing Evidence-Based Crieteria for Initiating Treatment fo NF1-OPG. awarded by Children's Tumor Foundation 2015 - 2021
  • Phase I study of PD-0332991 for pediatric patiens with retinoblastoma protein (RB)-positive recurrent or refractory central nervous system (CNS) tumors. awarded by Pfizer, Inc. 2014 - 2021
  • Visual Field Outcomes in Pediatric Patients with NF1-associated Optic Pathway Gliomas awarded by Boston Children's Hospital 2018 - 2019
  • Expansion of the AYA Oncology Initiative at Duke University awarded by St. Baldrick's Foundation 2016 - 2018
  • Dissecting the role of injury is sarcoma formation awarded by Sarcoma Alliance for Research Through Collaboration 2015 - 2017
  • Dissecting the role of injury is sarcoma formation awarded by Sarcoma Alliance for Research Through Collaboration 2015 - 2017
• 

  External Relationships

  • AstraZeneca
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Just, Marissa A., David Van Mater, and Lars M. Wagner. “Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.” Pediatr Blood Cancer, April 24, 2021, e29084. https://doi.org/10.1002/pbc.29084.
       Full Text  Link to Item
    • Van Mater, David, Sridharan Gururangan, Oren Becher, Olivia Campagne, Sarah Leary, Joanna J. Phillips, Jie Huang, et al. “A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).” Pediatr Blood Cancer 68, no. 4 (April 2021): e28879. https://doi.org/10.1002/pbc.28879.
       Full Text  Link to Item
    • Keskinyan, Vahakn S., David H. Noyd, Caroline M. Underwood, and David Van Mater. “Sweet Syndrome in Pediatric Acute Myeloid Leukemia.” J Pediatr Hematol Oncol 43, no. 1 (January 2021): 31–32. https://doi.org/10.1097/MPH.0000000000001900.
       Full Text  Link to Item
    • Hecht, Anna, Julia A. Meyer, Astrid Behnert, Eric Wong, Farid Chehab, Adam Olshen, Aaron Hechmer, et al. “Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.” Haematologica Online ahead of print (December 30, 2020). https://doi.org/10.3324/haematol.2020.270595.
       Full Text  Link to Item
    • Gillespie, N. J., and D. van Mater. “Genitourinary manifestations of hereditary cancer predisposition syndromes in children.” Translational Andrology and Urology 9, no. 5 (October 1, 2020): 2331–47. https://doi.org/10.21037/tau-2019-pum-09.
       Full Text
    • Robles, Joanna, Vahakn S. Keskinyan, Matthew Thompson, Joseph T. Davis, and David Van Mater. “Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.” Pediatr Hematol Oncol 37, no. 5 (August 2020): 445–49. https://doi.org/10.1080/08880018.2020.1735591.
       Full Text  Link to Item
    • Lee, Chang-Lung, Yvonne M. Mowery, Andrea R. Daniel, Dadong Zhang, Alexander B. Sibley, Joe R. Delaney, Amy J. Wisdom, et al. “Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma.” Jci Insight 4, no. 13 (July 11, 2019). https://doi.org/10.1172/jci.insight.128698.
       Full Text  Link to Item
    • Bose, Shree, Joanna Robles, Chad M. McCall, Anand S. Lagoo, Daniel S. Wechsler, Gary R. Schooler, and David Van Mater. “Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.” Pediatr Blood Cancer 66, no. 1 (January 2019): e27491. https://doi.org/10.1002/pbc.27491.
       Full Text  Link to Item
    • Lee, Sulgi, Madhuri Kambhampati, M Isabel Almira-Suarez, Cheng-Ying Ho, Eshini Panditharatna, Seth I. Berger, Joyce Turner, et al. “Somatic Mosaicism of IDH1 R132H Predisposes to Anaplastic Astrocytoma: A Case of Two Siblings.” Front Oncol 9 (2019): 1507. https://doi.org/10.3389/fonc.2019.01507.
       Full Text  Link to Item
    • Van Mater, David, and Lars Wagner. “Management of recurrent Ewing sarcoma: challenges and approaches.” Onco Targets Ther 12 (2019): 2279–88. https://doi.org/10.2147/OTT.S170585.
       Full Text  Link to Item
    • Van Mater, David, Eric Xu, Anupama Reddy, Leonor Añó, Mohit Sachdeva, Wesley Huang, Nerissa Williams, et al. “Injury promotes sarcoma development in a genetically and temporally restricted manner.” Jci Insight 3, no. 20 (October 18, 2018). https://doi.org/10.1172/jci.insight.123687.
       Full Text  Link to Item
    • Narine, Kalindi Y., Christopher C. Oh, Herbert E. Fuchs, and David Van Mater. “Calvarial mass as a presenting feature of neurofibromatosis type 2 in a pediatric patient.” Am J Med Genet A 176, no. 1 (January 2018): 246–47. https://doi.org/10.1002/ajmg.a.38505.
       Full Text  Link to Item
    • Huang, Jianguo, Mark Chen, Melodi Javid Whitley, Hsuan-Cheng Kuo, Eric S. Xu, Andrea Walens, Yvonne M. Mowery, et al. “Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma.” Nat Commun 8 (July 10, 2017): 15999. https://doi.org/10.1038/ncomms15999.
       Full Text  Link to Item
    • Sayour, Elias J., Talal Mousallem, David Van Mater, Endi Wang, Paul Martin, Rebecca H. Buckley, and Raymond C. Barfield. “Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia.” Pediatr Blood Cancer 63, no. 10 (October 2016): 1856–59. https://doi.org/10.1002/pbc.26092.
       Full Text  Link to Item
    • Van Mater, David, Leonor Añó, Jordan M. Blum, Micah T. Webster, WeiQiao Huang, Nerissa Williams, Yan Ma, Diana M. Cardona, Chen-Ming Fan, and David G. Kirsch. “Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway.” Cancer Res 75, no. 3 (February 1, 2015): 605–14. https://doi.org/10.1158/0008-5472.CAN-14-2527.
       Full Text  Link to Item
    • Dodd, Rebecca D., Leonor Añó, Jordan M. Blum, Zhizhong Li, David Van Mater, and David G. Kirsch. “Methods to generate genetically engineered mouse models of soft tissue sarcoma.” Methods Mol Biol 1267 (2015): 283–95. https://doi.org/10.1007/978-1-4939-2297-0_13.
       Full Text  Link to Item
    • Sachdeva, Mohit, Jeffrey K. Mito, Chang-Lung Lee, Minsi Zhang, Zhizhong Li, Rebecca D. Dodd, David Cason, et al. “MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes.” J Clin Invest 124, no. 10 (October 2014): 4305–19. https://doi.org/10.1172/JCI77116.
       Full Text  Link to Item
    • Blum, Jordan M., Leonor Añó, Zhizhong Li, David Van Mater, Brian D. Bennett, Mohit Sachdeva, Irina Lagutina, et al. “Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.” Cell Rep 5, no. 4 (November 27, 2013): 933–40. https://doi.org/10.1016/j.celrep.2013.10.020.
       Full Text  Link to Item
    • Raizis, Anthony M., David Van Mater, Lauri A. Aaltonen, Dietmar Lohmann, Michelle S. Cheale, Vivienne M. Bickley, Peter M. George, Yaolin Zhou, and Philip M. Rosoff. “Trilateral retinoblastoma in a patient with Peutz-Jeghers syndrome.” Am J Med Genet A 161A, no. 5 (May 2013): 1096–1100. https://doi.org/10.1002/ajmg.a.35748.
       Full Text  Link to Item
    • Van Mater, David, Erik H. Knelson, Kathleen A. Kaiser-Rogers, and Michael B. Armstrong. “Neuroblastoma in a pediatric patient with a microduplication of 2p involving the MYCN locus.” Am J Med Genet A 161A, no. 3 (March 2013): 605–10. https://doi.org/10.1002/ajmg.a.35766.
       Full Text  Link to Item
    • Mater, David Van, Barbara K. Goodman, Endi Wang, Ana M. Gaca, and Daniel S. Wechsler. “MLL duplication in a pediatric patient with B-cell lymphoblastic lymphoma.” J Pediatr Hematol Oncol 34, no. 3 (April 2012): e120–23. https://doi.org/10.1097/MPH.0b013e3182273b57.
       Full Text  Link to Item
    • Papalas, John A., David Van Mater, and Endi Wang. “Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young.” Am J Dermatopathol 32, no. 8 (December 2010): 821–27. https://doi.org/10.1097/DAD.0b013e3181d81dc3.
       Full Text  Link to Item
    • Van Mater, David, Frank T. Kolligs, Andrzej A. Dlugosz, and Eric R. Fearon. “Transient activation of beta -catenin signaling in cutaneous keratinocytes is sufficient to trigger the active growth phase of the hair cycle in mice.” Genes Dev 17, no. 10 (May 15, 2003): 1219–24. https://doi.org/10.1101/gad.1076103.
       Full Text  Link to Item
    • Kolligs, Frank T., Marvin T. Nieman, Ira Winer, Gang Hu, David Van Mater, Ying Feng, Ian M. Smith, et al. “ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.” Cancer Cell 1, no. 2 (March 2002): 145–55. https://doi.org/10.1016/s1535-6108(02)00035-1.
       Full Text  Link to Item
    • Piwien-Pilipuk, G., D. Van Mater, S. E. Ross, O. A. MacDougald, and J. Schwartz. “Growth hormone regulates phosphorylation and function of CCAAT/enhancer-binding protein beta by modulating Akt and glycogen synthase kinase-3.” J Biol Chem 276, no. 22 (June 1, 2001): 19664–71. https://doi.org/10.1074/jbc.M010193200.
       Full Text  Link to Item
    • Dance, G. S., P. Beemiller, Y. Yang, D. V. Mater, I. S. Mian, and H. C. Smith. “Identification of the yeast cytidine deaminase CDD1 as an orphan C-->U RNA editase.” Nucleic Acids Res 29, no. 8 (April 15, 2001): 1772–80. https://doi.org/10.1093/nar/29.8.1772.
       Full Text  Link to Item
    • Siddiqui, J. F., D. Van Mater, M. P. Sowden, and H. C. Smith. “Disproportionate relationship between APOBEC-1 expression and apolipoprotein B mRNA editing activity.” Exp Cell Res 252, no. 1 (October 10, 1999): 154–64. https://doi.org/10.1006/excr.1999.4598.
       Full Text  Link to Item
    • Van Mater, D., M. P. Sowden, J. Cianci, J. D. Sparks, C. E. Sparks, N. Ballatori, and H. C. Smith. “Ethanol increases apolipoprotein B mRNA editing in rat primary hepatocytes and McArdle cells.” Biochem Biophys Res Commun 252, no. 2 (November 18, 1998): 334–39. https://doi.org/10.1006/bbrc.1998.9647.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.